Covaxin, India's first indigenous corona vaccine, shows efficacy of 81 percent

A- A A+

Last Updated : Apr 15 2021 8:03AM Screen Reader Access

News Highlights

Govt cancels CBSE Exam for Class 10th; postpones Class 12th exams; PM Modi says well-being of students is top priority of govt VP M Venkaiah Naidu and PM Modi interact with Governors and LGs on COVID-19 situation in country Centre approves increase in production of Remdesivir and reducing its prices Strict restrictions come into effect in Maharashtra for a fortnight from tonight to curb spread of COVID-19 pandemic Health Minister Dr Harsh Vardhan launches Aahaar Kranti mission to spread awareness about nutrition

National News

Mar 04, 2021

1:19PM

Covaxin, India's first indigenous corona vaccine, shows efficacy of 81 percent

@BharatBiotech

Indigenous Covid-19 vaccine Covaxin has demonstrated interim clinical efficacy of 81 per cent in its phase three trial. The trial involved 25 thousand 800 participants across 21 sites.

The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group resulting in vaccine efficacy of 81 per cent.

The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research.

Director-General of Indian Council of Medical Research, Dr. Balram Bhargava said that the journey of completely indigenous COVID-19 vaccine in less than eight months’ time showcases the immense strength of Atmanirbhar Bharat. He said, it is also a testament to India’s emergence as a global vaccine superpower.

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said that Covaxin demonstrated high clinical efficacy against Covid-19 and significant immunogenicity against the rapidly emerging variants.